ATE435856T1 - Vitamin-d-rezeptormodulatoren vom phenyl-thiophen-typ - Google Patents

Vitamin-d-rezeptormodulatoren vom phenyl-thiophen-typ

Info

Publication number
ATE435856T1
ATE435856T1 AT03728782T AT03728782T ATE435856T1 AT E435856 T1 ATE435856 T1 AT E435856T1 AT 03728782 T AT03728782 T AT 03728782T AT 03728782 T AT03728782 T AT 03728782T AT E435856 T1 ATE435856 T1 AT E435856T1
Authority
AT
Austria
Prior art keywords
vitamin
receptor modulators
phenyl thiophene
thiophene type
phenyl
Prior art date
Application number
AT03728782T
Other languages
English (en)
Inventor
Karl Dahnke
Robert Gajewski
Charles Jones
Jared Linebarger
Jianliang Lu
Tianwei Ma
Sunil Nagpal
Todd Simard
Ying Yee
Emilio Bunel
Ryan Stites
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE435856T1 publication Critical patent/ATE435856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hard Magnetic Materials (AREA)
  • Liquid Crystal Substances (AREA)
AT03728782T 2002-05-29 2003-05-22 Vitamin-d-rezeptormodulatoren vom phenyl-thiophen-typ ATE435856T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38415102P 2002-05-29 2002-05-29
PCT/US2003/014539 WO2003101978A1 (en) 2002-05-29 2003-05-22 Phenyl-thiophene type vitamin d receptor modulators

Publications (1)

Publication Number Publication Date
ATE435856T1 true ATE435856T1 (de) 2009-07-15

Family

ID=29711986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03728782T ATE435856T1 (de) 2002-05-29 2003-05-22 Vitamin-d-rezeptormodulatoren vom phenyl-thiophen-typ

Country Status (16)

Country Link
US (1) US7601850B2 (de)
EP (2) EP2184281A1 (de)
JP (1) JP4664069B2 (de)
CN (1) CN100471853C (de)
AT (1) ATE435856T1 (de)
AU (1) AU2003233505B2 (de)
BR (1) BR0309983A (de)
CA (1) CA2485503C (de)
CY (1) CY1109341T1 (de)
DE (1) DE60328286D1 (de)
DK (1) DK1511740T3 (de)
ES (1) ES2327629T3 (de)
MX (1) MXPA04011903A (de)
PT (1) PT1511740E (de)
SI (1) SI1511740T1 (de)
WO (1) WO2003101978A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011903A (es) * 2002-05-29 2005-03-31 Lilly Co Eli Moduladores de receptor de vitamina d tipo fenil-tiofeno.
WO2004002530A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
BR0316401A (pt) 2002-11-22 2006-02-21 Lilly Co Eli composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto
US20060135484A1 (en) * 2003-01-10 2006-06-22 Eli Lilly And Company Patent Divison Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
JP4589336B2 (ja) * 2003-11-20 2010-12-01 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
JP4717005B2 (ja) * 2003-11-20 2011-07-06 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005051893A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
ES2307069T3 (es) 2003-11-20 2008-11-16 Eli Lilly And Company Compuestos de fenilfurano como moduladores del receptor de la vitamina d.
ES2322962T3 (es) * 2004-12-21 2009-07-02 Eli Lilly And Company Moduladores del receptor de la vitamina d.
MX2007007225A (es) 2004-12-21 2007-08-21 Lilly Co Eli Moduladores del receptor de la vitamina d.
TW200716536A (en) 2005-06-09 2007-05-01 Chugai Pharmaceutical Co Ltd Vitamin D compounds
JP2009528344A (ja) * 2006-02-28 2009-08-06 アストラゼネカ・アクチエボラーグ インドール誘導体の新規な塩及び医薬におけるその使用
UA111709C2 (uk) * 2009-12-16 2016-06-10 Пола Кемікал Індастріз Інк. Застосування похідних n-бензоїлсерину для запобігання або ослаблення пігментації
EP2794556B1 (de) 2011-12-21 2018-04-18 Gleason, James L. Bis-(aryl/heteroaryl)-methylenverbindungen, pharmazeutische zusammensetzungen damit und deren verwendung zur behandlung von krebs
CN103193695B (zh) * 2013-04-22 2015-08-05 中国药科大学 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
CA3073810A1 (en) * 2017-08-31 2019-03-07 Ahammune Biosciences Private Limited Thiophene-derived compounds, process for synthesis and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1137733B (de) * 1954-06-05 1962-10-11 Chem Fab Promonta G M B H Verfahren zur Herstellung von Aryl- und Thienylmethylphenylalkylaminen
JPS5818560A (ja) * 1981-07-23 1983-02-03 Nissan Motor Co Ltd 内燃機関用配電器
JPH02235854A (ja) * 1989-03-08 1990-09-18 Nippon Soda Co Ltd 置換ｎ―フェニル―チオ尿素、―イソチオ尿素及び―カルボジイミド並びにそれらの製法及び殺虫・殺ダニ剤
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
CA2253862A1 (en) * 1996-05-16 1997-11-20 Wai C. Wong Dihydropyrimidines and uses thereof
DE19718334A1 (de) 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
FR2801307B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
FR2801305B1 (fr) * 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
MXPA04011903A (es) * 2002-05-29 2005-03-31 Lilly Co Eli Moduladores de receptor de vitamina d tipo fenil-tiofeno.
BR0316401A (pt) 2002-11-22 2006-02-21 Lilly Co Eli composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto
US20060135484A1 (en) 2003-01-10 2006-06-22 Eli Lilly And Company Patent Divison Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
WO2004063345A2 (en) 2003-01-10 2004-07-29 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
ATE455749T1 (de) 2003-10-14 2010-02-15 X Ceptor Therapeutics Inc Verbindungen mit verbrückten ringen als pharmazeutische mittel
JP4717005B2 (ja) 2003-11-20 2011-07-06 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
ES2291981T3 (es) 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
JP4589336B2 (ja) 2003-11-20 2010-12-01 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
WO2005051893A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
ES2307069T3 (es) 2003-11-20 2008-11-16 Eli Lilly And Company Compuestos de fenilfurano como moduladores del receptor de la vitamina d.
ES2322962T3 (es) 2004-12-21 2009-07-02 Eli Lilly And Company Moduladores del receptor de la vitamina d.
MX2007007225A (es) 2004-12-21 2007-08-21 Lilly Co Eli Moduladores del receptor de la vitamina d.

Also Published As

Publication number Publication date
BR0309983A (pt) 2005-02-22
WO2003101978A1 (en) 2003-12-11
CN100471853C (zh) 2009-03-25
DK1511740T3 (da) 2009-08-24
CA2485503A1 (en) 2003-12-11
CN1656089A (zh) 2005-08-17
JP4664069B2 (ja) 2011-04-06
US7601850B2 (en) 2009-10-13
CY1109341T1 (el) 2014-07-02
JP2005532348A (ja) 2005-10-27
AU2003233505A1 (en) 2003-12-19
EP1511740B1 (de) 2009-07-08
ES2327629T3 (es) 2009-11-02
CA2485503C (en) 2011-07-19
US20060287536A1 (en) 2006-12-21
PT1511740E (pt) 2009-08-10
EP2184281A1 (de) 2010-05-12
DE60328286D1 (de) 2009-08-20
EP1511740A1 (de) 2005-03-09
AU2003233505B2 (en) 2009-04-23
SI1511740T1 (sl) 2009-12-31
MXPA04011903A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
CY1109341T1 (el) Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
DK1565422T3 (da) Vitamin-D-receptor-modulatorer
ATE370941T1 (de) Modulatoren des vitamin-d-rezeptors
WO2005051893A3 (en) Vitamin d receptor modulators
DE69911596D1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
DE60219655D1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
EA200001258A1 (ru) Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
ATE396982T1 (de) Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
ATE535239T1 (de) Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrin
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
DE69912598D1 (de) 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon
MY140767A (en) Compounds, methods and compositions
ES2155134T3 (es) Derivados de imidazolidina y su utilizacion.
DE60324909D1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta-methyl-19-nor vitamin d3 und ihre verwendung
UY26130A1 (es) Compuestos para tratar la obesidad
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
EP1482973A4 (de) Verfahren zur modulierung von cd200-rezeptoren
WO2005051898A3 (en) Vitamin d receptor modulators
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
AU2003233735A8 (en) 24-sulfoximine vitamin d3 compounds
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
EP1576180A4 (de) Komponenten des ampk-wegs
BRPI0515670A (pt) anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
BR9902665A (pt) Composição fungicida para plantas de arrozais, e, processo para o controle de doenças de plantas de arrozais

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1511740

Country of ref document: EP